Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Invesco LLC slashed its Amgen holdings by 20.2%, unloading 2,310 shares worth roughly $2.85 million. This sale brought ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $288.00. The company’s shares closed yesterday at ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Amgen (AMGN – Research Report) yesterday. The company’s shares closed yesterday at $277.49. Confident Investing Sta ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...